Alnylam Presents New Pre-clinical Data on ALN-AAT

Alnylam Pharmaceuticals

announced today that it has presented new pre-clinical data with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in … Alnylam Pharmaceuticals (NASDAQ: ALNY announced today that it has presented new pre-clinical data with ALN-AAT, an RNAi therapeutic targeting alpha-1 antitrypsin (AAT) in development for the treatment of liver disease associated with AAT deficiency. These data were presented in a poster entitled “Developing an RNAi Therapeutic for Liver Disease Associated with Alpha-1-Antitrypsin Deficiency” at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, “The Liver Meeting”) held November 1 – 5, 2013 in Washington, D.C. AAT deficiency liver disease is a rare genetic disorder, with the most common mutation being in the “Z-allele,” which results in the accumulation of the mutant AAT protein (Z-AAT)